Obsessive-Compulsive Disorder
An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
Subtype terms (3)
More specific conditions that are subtypes of Obsessive-Compulsive Disorder in the MeSH hierarchy.
- Excoriation Disorder
- Hoarding Disorder
3 drugs approved
- Trichotillomania
12 drugs (9 approved, 3 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (16)
Phase 3 trials (5)
Phase 2 trials (34)
- nitrous oxide
- sarcosine
- agomelatine
- oxytocin
- acetylcysteine
- nabilone
- lamotrigine
- ketamine
- cannabidiol
- naltrexone
- hypericum perforatum
- nitrogen
- dronabinol
- flumazenil
- risperidone
- bitopertin
- celecoxib
- cannabis
- 3,4-Methylenedioxymethamphetamine
- paliperidone
- valbenazine
- xenon xe-133
- human fecal microbiota
- aripiprazole
- midazolam
- rituximab
- psilocybin
- sodium chloride
- minocycline
- dextromethorphan
- +4 more
Phase 1 trials (3)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (40)
- Forest Laboratories
- AstraZeneca
- Novartis
- Hamilton Health Sciences Corporation
- Lallemand SAS
- Rogers Center for Research & Training, Inc.
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute of Mental Health and Neuro Sciences, India
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Harvard University
- McMaster University
- New York University
- Osaka City University
- Seoul National University
- University of Florence
- University of Florida
- University of Ottawa
- University of Bergen
- Columbia University
- Creighton University
- University of Cambridge
- University of Copenhagen
- Icahn School of Medicine at Mount Sinai
- Free University of Amsterdam
- Jiao Tong University
- Karolinska Institute
- Janssen Pharmaceutica NV
- University of Sao Paulo
- +10 more
Organization Involved with Phase 3 Indications (13)
- AbbVie
- Meiji Seika Pharma Co., Ltd.
- Abarbanel Mental Health Center
- University of Pennsylvania
- Duke University
- Hoosier Cancer Research Network
- University of South Florida
- University of California, Los Angeles
- University of Chicago
- University of Connecticut
- Center Abarbanel Mental Health
- Biohaven Pharmaceuticals Inc.
- Saban Family Foundation
Organization Involved with Phase 2 Indications (49)
- Servier
- Roche
- Neuropharm
- Orexigen Therapeutics, Inc
- Transcept Pharmaceuticals
- Repligen Corporation
- National Center for Complementary and Integrative Health (NCCIH)
- National Center for Research Resources (NCRR)
- University of Arizona
- Baylor University
- Cornell University
- Indiana University
- Kunming Medical University
- Mclean Hospital
- Nanjing Medical University
- Parkway Medical Center
- Stanford University
- Sichuan University
- Yale University
- Taipei Medical University
- Tel Aviv University
- Nanchang University
- University of British Columbia
- Uppsala University
- University of Minnesota
- Jinan University
- Columbia-NYSPI-RFMH
- Atlanta Center for Medical Research
- California Clinical Trials
- Henan Medical University
- +19 more
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (9)